FDA tissue inspections
This article was originally published in The Gray Sheet
Executive Summary
An inspection "blitz" on companies that recover human tissues for transplantation found no significant compliance problems, FDA's Human Tissue Task Force 1reports June 12. FDA inspected 153 U.S. tissue recovery firms from October 2006 through March 2007, and while some deviations from FDA's tissue regulations were found, there were no major deficiencies that could put patients at risk for disease transmission, the report says. The task force, which called for the inspections after serious violations were discovered at two tissue recovery firms last year, recommends that human tissue companies performing the highest-risk manufacturing steps be inspected every two years, and all others every three years (2"The Gray Sheet" Sept. 4, 2006, In Brief). FDA plans 484 tissue-facility inspections in fiscal 2007. More than 2,000 human cell and tissue establishments are registered with FDA, with 1.5 million musculoskeletal tissue transplants performed each year...
You may also be interested in...
FDA introduces human tissue task force
The group is charged to assess the effectiveness of new tissue regulations that took effect in May 2005, focusing on recent findings that some tissue recovery establishments do not follow federal requirements, the agency said Aug. 30 (1"The Gray Sheet" Nov. 22, 2004, p. 6). "The creation of this task force is part of the agency's overall plan to ensure that all human cells and tissues are as safe as possible," said Jesse Goodman, MD, director of the Center for Biologics Evaluation & Research. On Aug. 18, FDA ordered Donor Referral Services to cease manufacturing of human cells, tissues and cellular and tissue-based products and to retain all such products. An FDA inspection of the Raleigh, N.C., operation found "serious" violations of manufacturing procedures and recordkeeping requirements...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.